Morning Wire
Pill Politics: The Supreme Battle Over Mifepristone | Saturday Extra
Mar 23, 2024
Erin Hawley, a senior counsel at Alliance Defending Freedom and lead attorney in the pivotal Supreme Court case on mifepristone, dives into the contentious issues surrounding this abortion drug. She discusses the rise in medication abortions and the critical role of initial doctor visits in ensuring safety. Hawley highlights the alarming health risks of mifepristone, including severe complications and regulatory changes during the pandemic. Legal arguments surrounding the FDA's oversight and patient safety concerns add further depth to this critical societal debate.
10:28
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- At-home abortions with Mifepristone are increasing, with FDA safeguards being questioned.
- Supreme Court case focuses on regulating access to Mifepristone, highlighting risks of minimal medical oversight.
Deep dives
Increasing Popularity of At-Home Abortions
At-home abortions using medication have been on the rise, with six in ten abortions in 2023 being performed this way, up from 53 percent in 2020. The data from the Gutmacher Institute highlights the trend towards at-home abortions becoming the preferred method. The Supreme Court is set to address a case aiming to restrict access to abortion drug Mifepristone, which can currently be obtained through mail without medical supervision.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
